Immunogenic composition
AssigneeGlaxosmithkline Biologicals SA
InventorsAmirreza Faridmoayer, Rainer Follador, Stefan Jochen Kemmler, Michael Thomas Kowarik, Gerald Johann Posch, Fabio Serventi
Life of this patent
Estimating the term…
Abstract
The disclosure provides synthetic (e.g. recombinant) pneumococcal saccharides comprising one or more repeat unit(s) →4)-β-D-Glcp-(1→4)-[Gro-(2→P→3)]-β-D-Galp-(1→4)-β-L-Rhap-(1→. Also provided are conjugates comprising a →4)-β-D-Glcp-(1→4)-[Gro-(2→P→3)]-β-D-Galp-(1→4)-β-L-Rhap-(1→, immunogenic compositions, vaccines and their use in preventing or treating infection by Streptococcus pneumoniae.
Claims13
A vaccine comprising an immunogenic composition comprising an immunologically effective amount of a polysaccharide-carrier protein conjugate,
- wherein the polysaccharide comprises one or more and less than 500 repeat unit(s) Glcp-(1→4)-[Gro-(2→P→3)]-β-D-Galp-(1→4)-β-L-Rhap-(1→,
- wherein the polysaccharide is a hybrid oligosaccharide or polysaccharide having a structure:
- (B)n-A→wherein A is an oligosaccharide containing at least 2, 3, 4, 5, 6, 7 or 8 monosaccharides with a hexose monosaccharide derivative at the reducing end (indicated by the arrow in the diagram), wherein the hexose monosaccharide derivative is N-acetylglucosamine (GlcNAc), N-acetylgalactoseamine (GalNAc), 2,4-Diacetamido-2,4,6-trideoxyhexose (DATDH), N-acetylfucoseamine (FucNAc), or N-acetylquinovosamine (QuiNAc);
- wherein B is an oligosaccharide repeat unit >4)-B-D-Glcp-(1→4)-[Gro-(2→P→3)]-β-D-Galp-(1→4)-β-L-Rhap-(1→;
- and wherein n is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or at least 20;
- and
- wherein the immunogenic composition comprises 10 or more capsular saccharides from different S. pneumoniae serotypes conjugated to a carrier protein.
Dependencies are inferred from the claim text.